industry pr

Press release news from the public relations clients of Tiziani Whitmyre, Inc.

Posts Tagged ‘Boston’


Monday, November 26th, 2012

Immunetics, Inc. Names John Yonkin as CEO

Boston, Mass. — November 26, 2012Immunetics, Inc., an innovative developer of state-of-the-art assay technology for infectious disease diagnosis and blood screening, today announced that the company’s Board of Directors has appointed John Yonkin as Chief Executive Officer.

Mr. Yonkin will assume the post of CEO effective December 1, 2012. He will also serve as a member of the Board of Directors.

Mr. Yonkin brings more than 25 years of business experience in the clinical diagnostics field to Immunetics. Previously, he served as Vice President for Strategic Projects at Alere, Inc., and as President of Alere’s predecessor, Inverness Medical Innovations. While at Alere, he was the lead executive responsible for the integration of Biosite, Inc., following its acquisition by Alere in 2007. At Inverness, Mr. Yonkin was President of Nutritionals and Pharmaceuticals from 2005-2007, and Vice President of U.S. Sales and Marketing from 2001-2005. His previous experience includes positions managing sales and marketing and product development at Baxter, Genzyme, and Inverness.

“I am very excited to be joining the very talented scientific team at Immunetics as the company prepares to bring to market the innovative BacTx® rapid test for bacterial contamination of platelets,” Mr. Yonkin said.

The BacTx test addresses a critical, global infectious risk in transfusion, caused by the  estimated 1 in 2,000 platelet units that are contaminated with bacteria. Medical studies are increasingly showing that such contamination is a significant cause of illness and death among transfusion recipients. Worldwide, more than 10 million platelet units are collected per year.

Immunetics received U.S. Food and Drug Administration (FDA) clearance for its BacTx test in June 2012. The company has issued patents on the BacTx technology, which was initially developed with support from the National Institutes of Health.

Mr. Yonkin succeeds Dr. Andrew Levin, the company’s founder. Dr. Levin will remain President at Immunetics and will continue to lead the Research and Development group.

About Immunetics

Immunetics, Inc. offers state-of-the-art assay technology for infectious disease diagnosis and blood screening, and for more than ten years has been a leading innovator of tests for bacterial, viral, and parasitic diseases. The produces and markets a range of infectious disease assay kits and instruments. The company has issued patents on its BacTx® test for bacterial contamination of platelets. It has developed and markets other FDA-cleared products, including a test for Lyme disease, and is actively working on new tests for Babesiosis and Chagas disease — both of which are emerging risks to the blood supply. Immunetics is headquartered in Boston. The company’s mission is to deliver better, cost-efficient care through more accurate diagnosis. For more information, visit the Immunetics website at http://www.immunetics.com.


Tuesday, September 25th, 2012

Boston Seminar to Assist Medical Device & Pharmaceutical Manufacturers with Environmental Monitoring, Risk-Assessment

Microtest Laboratories will present an environmental monitoring seminar and risk-assessment workshop to assist medical device and pharmaceutical manufacturers with building, validating, and maintaining their clean rooms and sterile manufacturing environments.

Titled “Environmental Monitoring Seminar and Risk-Assessment Workshop,” the event will provide practical information and the latest techniques on cleaning and disinfection programs designed to maintain aseptic conditions and prevent microbial contamination.

The event will be held at the MIT Endicott House in Dedham, Mass. — just outside Boston — on Wednesday, October 24, 2012, from 10 a.m. to 2 p.m.

At the event, attendees will:

  • Participate in a hands-on workshop that focuses on risk assessment in the clean room
  • Discover the best practices for qualifying and maintaining a clean room facility
  • Identify and assess the risks commonly found in a clean room environment
  • Test the information they’ve learned in a mock clean room floor plan exercise

A networking reception, and lunch, is included. For more information, or to RSVP, contact Julie Adamski at Microtest Laboratories by phone at 1-800-631-1680, ext. 192, or by email at jadamski@microtestlabs.com. Registration for the event is $149.

The event is one in a series of technical seminars and workshops for medical device and pharmaceutical manufacturers presented by Microtest Laboratories, a Mass.-based, FDA-audited company with a history of exceptional regulatory compliance. Microtest’s environmental sciences group helps its clients maintain control of theircontrolled environments and is a proven resource for contamination testing needs arising from the manufacturing of medical devices or pharmaceuticals, as well as sterile compounding in hospital pharmacies.

About Microtest Laboratories
Microtest Laboratories is a leader in testing services and contract manufacturing for the medical device, pharmaceutical, and biotechnology industries. Based in Agawam, Massachusetts, USA, the company provides expertise and flexible processes that enhance product safety and security, accelerate time to market, and minimize supply chain disruption. For more information, visit http://www.microtestlabs.com or call 1-413-786-1680 or toll-free 1-800-631-1680. Follow Microtest Laboratories on Twitter @MicrotestLabs at http://twitter.com/MicrotestLabs.

###


Monday, September 10th, 2012

Immunetics Receives $3.7 Million NIH Contract for Babesia Blood Screening Test

— Will Carry Out Clinical Trials with Blood Systems Research Institute,
Creative Testing Solutions

BOSTON — September 10, 2012 — Immunetics, Inc., has received a $3.7 million, two year SBIR contract from the National Heart, Lung and Blood Institute, an agency of the National Institutes of Health (NIH), to support clinical trials of a new blood screening test for Babesia infection.

“Babesia is among the top infectious threats to blood safety and, at present, there is no licensed test available. The NIH contract will allow us to address this gap in blood safety with the first cost-effective test designed for high-throughput screening of the blood supply.  We are honored to have been entrusted by NIH to carry out this public health mission,” said Andrew E. Levin, Ph.D., Immunetics Chief Executive Officer and Scientific Director.

Babesia is a parasite which is transmitted by the same ticks that transmit Lyme disease. While it is often asymptomatic in healthy people, Babesia infection can lead to severe or fatal illness, especially in immunocompromised patients. The parasites can remain viable in blood donations and infect transfusion recipients. In recent years, nine fatal cases of transfusion-transmitted babesiosis have been reported. Surveillance carried out by the Centers for Disease Control and Prevention (CDC) revealed over 1,000 cases of infection nationwide in 2011 — a number that appears to be growing. The US Food & Drug Administration (FDA) sponsored a workshop in 2008 focused on Babesiosis as an emerging threat to the blood supply, and the Blood Products Advisory Committee convened a meeting in 2010 to advise the FDA on approaches to blood screening for Babesia.

The contract award will enable Immunetics to bring its Babesia test, developed under initial NIH support, through clinical trials and regulatory licensure. The trials will be carried out in collaboration with Blood Systems Research Institute of San Francisco, Calif., and Creative Testing Solutions of Tempe, Ariz. Creative Testing Solutions currently tests about 25% of the US blood supply, including regions endemic for the parasitic agent. The Babesia test will initially be made available through Creative Testing Solutions’ laboratories.

“We look forward to partnering with Immunetics and BSRI in the development and FDA approval process of a Babesia assay for use in blood screening,” said Creative Testing Solutions President Sally Caglioti. “It is always our intent to offer innovative services that provide our customers with the best donor testing possible. Active collaboration in the development of diagnostic tests that fit the immediate needs of the blood banking community is the next logical step to support CTS’ mission.”

“When the screening test identifies antibody-reactive donors, we will enroll and conduct rigorous testing of donation-derived and follow-up samples from those donors so that we can more fully understand the natural history of Babesia infection in asymptomatic donors,” said Michael P. Busch, M.D., Ph.D., Blood Systems Research Institute Director and Senior Vice President for Research and Scientific Affairs at Blood Systems. “The information that we derive will help guide the development of policies on how the test can be used most effectively. It will also determine whether and how donors who have had a positive result on the screening test could safely donate in the future.”

For more information, visit the company’s website at http://www.immunetics.com or call 1-617-896-9100 or toll-free 1-800-227-4765.

Immunetics is a leading developer and provider of innovative tests for a variety of bacterial, viral, and parasitic diseases. Recently, the company received FDA clearance for its BacTx® test for bacterial contamination in platelets. The company has developed and markets other FDA-cleared products, including a test for Lyme disease, and is actively working on new tests for HIV and Chagas disease — both of which are known or emerging risks to the blood supply.

About Immunetics

Immunetics Inc. (http://www.immunetics.com) offers state-of-the-art assay technology for infectious disease diagnosis and blood screening, and for more than ten years has been a leading innovator of tests for bacterial, viral, and parasitic diseases. The company produces and markets a range of infectious disease assay kits and instruments. Its mission is to deliver better, cost-efficient care through more accurate diagnosis. Immunetics is headquartered in Boston. Follow Immunetics on Twitter at http://twitter.com/immunetics.

About Creative Testing Solutions

Creative Testing Solutions (www.myCTS.org), a joint venture of Blood Systems and Florida-based OneBlood, is the largest independent blood donor testing laboratory in the United States, specializing in high-volume blood donor testing and infectious disease reference work. This non-profit organization, headquartered in Tempe, Arizona, tests nearly 4.5 million samples annually at three national laboratories in Dallas, Phoenix and Tampa that, combined, provide testing for more than 25 percent of the U.S. blood supply.

About Blood Systems

Blood Systems (www.bloodsystems.org) is one of the nation’s oldest and largest non-profit community blood service providers and operates community blood centers serving more than 500 hospitals in 18 states, biological products distribution services, a quality consulting group and a world-renowned transfusion medicine research institute.

# # #


Wednesday, May 30th, 2012

Clean Room Environmental Best Practices for Medical Device & Pharmaceutical Manufacturers are Focus of Boston Seminar on June 6

AGAWAM, MASS. – May 30, 2012 – Sterile manufacturing environments at medical device and pharmaceutical companies require effective cleaning and disinfection programs to maintain aseptic conditions and prevent microbial contamination. To help, laboratory testing experts will present “Clean Room Environmental Best Practices,” a special seminar in Boston on Wednesday, June 6, 2012.

The seminar is designed for all professionals responsible for building, validating, and maintaining controlled environments in the medical device and pharmaceutical industries. The program will include technical presentations on:

• Best practices for qualifying and maintaining clean room facilities

• “The people factor” in terms of containment control

• Qualifying and evaluating clean room disinfectants

• Difficult challenges: Practical advice and solutions

Opportunities for questions and continuing interaction will be encouraged.

Clean Room Environmental Best Practices” is scheduled for 10 a.m. to 2 p.m. on Wednesday, June 6, 2012, at the MIT Endicott House, 80 Haven Street, Dedham, Massachusetts — located just minutes from Boston. The cost is $149. Breakfast, lunch, and networking opportunities are included.

The seminar is sponsored by Microtest Laboratories, a Massachusetts-based, FDA-audited company with a history of exceptional regulatory compliance. Microtest’s environmental sciences group helps its clients maintain control of their controlled environments and is a proven resource for contamination testing needs arising from the manufacturing of medical devices or pharmaceuticals, as well as sterile compounding in hospital pharmacies.

For more information, contact Julie Adamski, toll-free, at 1-800-631-1680, ext. 192, or jadamski@microtestlabs.com.

About Microtest Laboratories

Microtest Laboratories is a leader in testing services and contract manufacturing for the medical device, pharmaceutical, and biotechnology industries. Based in Agawam, Massachusetts, USA, the company provides expertise and flexible processes that enhance product safety and security, accelerate time to market, and minimize supply chain disruption. For more information, visit http://www.microtestlabs.com or call 1-413-786-1680 or toll-free 1-800-631-1680. Follow Microtest Laboratories on Twitter @MicrotestLabs at http://twitter.com/MicrotestLabs.


Wednesday, May 2nd, 2012

Pharmaceutical Consultants are Focus of May 16th Conference in Boston

AGAWAM, MASS. — May 2, 2012 — Pharmaceutical consultants are invited to learn how to reap the benefits of single-source production and testing at a Pharmaceutical Consultants Conference sponsored by Microtest Laboratories on Wednesday, May 16, 2012, at the MIT Endicott House in Dedham, Massachusetts.

The conference will explore the wide range of new revenue and partnership opportunities that are available for pharmaceutical consultants leveraging Microtest Laboratories’ flexible, aseptic fill finish and combination product capabilities — as well as its complete portfolio of support testing services. Conference topics will include:

  • A virtual tour
  • Aseptic, combination product, clean fills
  • Supporting testing services
  • Environmental services
  • Partnership opportunities

The seminar is sponsored by Microtest Laboratories, a Massachusetts-based, FDA-audited company with a history of exceptional regulatory compliance.

The Pharmaceutical Consultants Conference is scheduled for 10 a.m. to 2 p.m. on Wednesday, May 16, 2012, at the MIT Endicott House, 80 Haven Street, Dedham, Massachusetts — located just minutes from Boston.

There’s no cost for qualified pharmaceutical consultants. Lunch and a networking reception are included.

For more information, visit the conference webpage at http://www.microtestlabs.com/conference, or contact Julie Adamski, toll-free, at 1-800-631-1680, ext. 192, or jadamski@microtestlabs.com.

About Microtest Laboratories

Microtest Laboratories is a leader in testing services and contract manufacturing for the medical device, pharmaceutical, and biotechnology industries. Based in Agawam, Massachusetts, USA, the company provides expertise and flexible processes that enhance product safety and security, accelerate time to market, and minimize supply chain disruption. For more information, visit http://www.microtestlabs.com or call 1-413-786-1680 or toll-free 1-800-631-1680. Follow Microtest Laboratories on Twitter @MicrotestLabs at http://twitter.com/MicrotestLabs.

 


Wednesday, September 21st, 2011

Building, Validating & Maintaining Controlled Environment Facilities is Focus of Oct. 18th Seminar in Boston Hosted by Microtest Laboratories

AGAWAM, Mass. — Building, validating, and maintaining a controlled environment facility is the subject of a daylong seminar on Oct. 18, 2011, hosted by Microtest Laboratories at the MIT Endicott House in Dedham, Massachusetts.

Titled “Keeping It Clean? The Building Blocks of Facility Control,” the seminar will focus on the clean room testing, disinfection validation, and related contamination testing issues that arise from manufacturing of medical devices or pharmaceuticals, as well as sterile compounding in hospital pharmacies.

In each seminar program, industry experts will present practice advice and sound solutions in an interactive format that will encourage a high level of engagement by participants for questions, answers and discussion. The topics will include:

  • Killing The Bugs Without Killing Yourself: Disinfectant Qualifications
  • Feeling Like A Fish Out of WFI?: Water System Validation and Maintenance
  • Got A Lot On Your Plate: Clean-room Validations and Maintenance
  • The Old In & Out: Considerations On Insourcing vs. Outsourcing

Keeping It Clean? The Building Blocks of Facility Control” will be presented 8:30 a.m. to 3:30 p.m. on Tuesday, Oct. 18, 2011, at the MIT Endicott House, 80 Haven Street in Dedham, Mass., just outside of Boston. Registration and a complimentary continental breakfast is at 8 a.m. Lunch will be served at Noon. The cost is $149 per person and includes meals, refreshments, and workshop handouts.

To register or for more information, visit the Microtest Laboratories website at http://www.microtestlabs.com/seminar/index.asp. Or, contact Julie Adamski at 413-786-1680, toll-free at 1-800-631-1680, or at jadamski@microtestlabs.com.

About Microtest Laboratories

Microtest Laboratories is a leader in controlled environment facility testing, laboratory testing, and contract manufacturing services for the medical device, pharmaceutical, and biotechnology industries. Based in Agawam, Massachusetts, USA, the company provides expertise and flexible processes that enhance product safety and security, accelerate time to market, and minimize supply chain disruption. For more information, visit http://www.microtestlabs.com or call 1-413-786-1680 or toll-free 1-800-631-1680. Follow Microtest Laboratories on Twitter @MicrotestLabs at http://twitter.com/MicrotestLabs.

# # #

Press contact: Don Goncalves, Tiziani Whitmyre, 1-781-793-9380, dgoncalves@tizinc.com

 


Tuesday, August 3rd, 2010

InQ Biosciences Appoints John Ryder as Senior Vice President, Sales & Marketing

Huntsville, Ala. and Marlborough, Mass., August 3, 2010InQ Biosciences Corporation, a provider of innovative technologies for cell growth and research, announced the appointment of John Ryder as Senior Vice President, Sales and Marketing. Ryder will be based in InQ’s sales office in Marlborough, Massachusetts.john-ryder-inqbiosciences

“Mr. Ryder’s responsibilities will include developing our sales channels, creating a strategic marketing plan, and building the InQ brand around the world,” said Dick Reeves, Chairman and Chief Executive Officer, InQ Biosciences.

“With his deep life sciences experience, he is the ideal executive to help us commercialize and launch the InQ Cell Research System. We are locating Mr. Ryder in the Boston area — the center of the stem cell and neuroscience research markets that will so greatly benefit from our exciting new technology,” Reeves said.

InQ is the first fully integrated system that creates a true in vivo environment for studying sensitive nerve, brain, and other human cells for disease research. It is the only cell research instrument that combines a dynamic software-controlled sample environment with powerful imaging and real-time data collection. These unique capabilities enable researchers to achieve unprecedented cell culture control, viability, and visibility that was previously unattainable.

Ryder brings over 20 years of life science sales, marketing, and business development leadership to InQ Biosciences. He joined the company from Skyscape, Marlborough, Massachusetts, a provider of trusted medical information for hand-held and mobile devices, where he was Senior Vice President of Sales. In that role, Ryder was instrumental in facilitating the acquisition of Skyscape in July 2009 by Physicians Interactive and Perseus, a $2 billion private equity firm. He also led sales and marketing for Advanced Instruments, Norwood, Massachusetts, a leading provider of microbiology research instrumentation to the pharmaceutical, industrial, and research markets. In addition, Ryder held sales management positions with Baxter Healthcare, Becton Dickinson Corporation, and Fisher Scientific. He holds a BS degree in Health Science Education from Springfield College in Massachusetts.

About InQ Biosciences
InQ Biosciences is a provider of innovative technologies for cell growth and research. The company’s InQ Cell Research System will empower scientists to unlock novel and more powerful approaches to cell-based discovery. The firm was founded in 2007 with technology originating from the University of Alabama in Huntsville. Series B financing was completed in May 2010 and commercial launch of its InQ system is scheduled for the fourth quarter of 2010. For more information, visit www.inqbio.com. Follow InQ Biosciences on Twitter at @InQbio (http://twitter.com/InQbio).

# # #

Public Relations contact, Boston:  Don Goncalves, dgoncalves@tizinc.com, 781-793-9380, for Tiziani Whitmyre Inc., http://www.tizinc.com/public-relations


Monday, July 19th, 2010

Harvest Time Bread Company Utilizes Tiziani Whitmyre, Inc. for Branding, Internet Marketing, Public Relations Services

logo5SHARON, Mass. – July 19, 2010 – Harvest Time Bread Company, a leading producer of a wide variety of breads, rolls, whole grain and organic products, is utilizing Tiziani Whitmyre, Inc. as its corporate branding, Internet marketing, and public relations services partner.

Tiziani Whitmyre (http://www.tizinc.com), is a Boston-area interactive marketing and public relations services agency that helps business-to-business (B2B) manufacturing and technology-based companies to build brands, gather sales leads, and generate an ROI which maximizes payback on marketing communications budgets.

Harvest Time Bread Company (http://www.harvesttimebread.com) is the proud maker of high-quality bakery products for grocers and food service companies across the U.S. Harvest Time specializes in artisan, European, and all-natural breads; distinctive sandwich rolls; and whole-grain and organic offerings. The company maintains facilities in Woodbridge, New Jersey, and Mount Airy, North Carolina, U.S.A. Backed by a heritage of more than 25 years of distinguished baking, Harvest Time Bread Company was established in its present form in 2005. The company recently announced a $4.5 million investment to expand its bakery operations in the Southeastern U.S.

Tiziani Whitmyre recently completed a wide-ranging brand image makeover for Harvest Time that included corporate branding, packaging, and a newly designed and optimized website. Tiziani Whitmyre will continue to promote Harvest Time product and service offerings to national and regional food service companies, restaurants, grocery stores, and retail chains around the U.S. through a variety of Internet marketing and ongoing public relations (PR) campaign.

About Tiziani Whitmyre
Tiziani Whitmyre (www.tizinc.com) is a Boston area-based marketing services and strategies agency that builds brands, generates sales leads, and delivers an ROI which maximizes payback on any marketing communications budget. Services include public relations (PR) services, Internet marketing online (including search engine optimization, affiliate marketing, web design), advertising, direct marketing, graphic design, and corporate branding strategy.

# # #

Public Relations contact, Boston:  Don Goncalves, dgoncalves@tizinc.com, 781-793-9380, for Tiziani Whitmyre Inc., http://www.tizinc.com/public-relations


Thursday, May 20th, 2010

Tiziani Whitmyre Releases White Paper On Performance Advertising Benefits for B2B Marketers

SHARON, MASS. – May 20, 2010 – TW Networks, a division of Boston-based marketing services firm Tiziani Whitmyre, Inc., has released a white paper that introduces the benefits of performance advertising for B2B marketers.

The paper, “Performance Advertising: How B2B Marketers Can Benefit from a New Pay-for-Performance Strategy,” explores how this new model exceeds the capabilities of traditional advertising for companies focused on lead generation and demand creation.

“The paper reviews how performance advertising changes the whole dynamic of online advertising,” said Rick Whitmyre, TW Networks president. “Instead of purchasing ad space based upon desired locations and ad frequency, marketers now can buy actual results.”

The paper defines the performance advertising model, reviews its strengths and applications, and provides case studies of companies that have successfully employed the strategy. It also discusses how the approach enhances marketing measurement and evaluation.

“In the paper, we describe how performance advertising provides marketers with insights that surpass traditional Web metrics — enabling measurements such as qualified lead generation and prospect conversion rates. These metrics permit marketers to perform real-time campaign customization and more accurate ROI calculation,” said Whitmyre.
Download a free copy of “Performance Advertising: How B2B Marketers Can Benefit from a New Pay-for-Performance Strategy” at: http://www.twnetworks.com/white-papers/performance-advertising.asp or call 781-793-9380.

About TW Networks

TW Networks (www.twnetworks.com) is the leader in online business-to-business (B2B) performance advertising. It is the only marketing firm that operates performance-based B2B networks reaching markets such as industrial automation and processing, OEM manufacturing, medical devices, pharmaceuticals, life sciences, utilities, oil and gas, logistics and supply chain, and electronics. The company offers a comprehensive portfolio of services that covers every step of the performance marketing process, including network and campaign development, commission structures, publisher and advertiser recruitment, network management, and creative services, plus campaign analytics, measurement, and optimization.

About Tiziani Whitmyre
Tiziani Whitmyre (www.tizinc.com) is a Boston area-based marketing services and strategies agency that builds brands, generates sales leads, and delivers an ROI which maximizes payback on any marketing communications budget. Services include Internet marketing online (including search engine optimization, affiliate marketing, web design), public relations (PR), advertising, direct marketing, graphic design, and corporate branding strategy.

# # #

Public Relations contact, Boston: Tiziani Whitmyre Inc., http://www.tizinc.com/public-relations


Wednesday, April 21st, 2010

First Commons Bank Assets Top $84 Million in Third Quarter of Operations

— New Newton-based bank surpasses more than 29% of all FDIC-insured banks nationally in just over eight months —

copy-of-1commonsbanklogoNewton, Massachusetts – April 21, 2010 – First Commons Bank, N.A. reported that its assets have grown to more than $84 million during its third quarter of operations ending March 31, 2010. The bank started operating on July 22, 2009 and serves businesses and individuals in Newton, Wellesley, Waltham, and eastern Massachusetts.

“First Commons Bank’s continued extraordinary asset growth has now placed us in the top 71% of all banks nationally,” said Tony Nuzzo, Chairman, President and Chief Executive Officer. “With almost 8,000 FDIC-insured banks in the US filing fourth quarter reports, our assets have surpassed more than 2,300 banks after approximately eight months of operations.”

“First Commons Bank is a common sense bank with quick loan decisions, easy access to decision makers, fair pricing, and great service,” said Nuzzo. “We are filling consumer and business voids created by the large banks and have recently added staff to intensify our focus on the commercial lending gaps in the marketplace.”

Nuzzo added, “Although we are pleased with our asset growth to-date as one measure of success, First Commons Bank is also focused on the bottom line.”

# # #

Public Relations contact, Boston: Tiziani Whitmyre Inc., http://www.tizinc.com/public-relations

About First Commons Bank
First Commons Bank, a nationally-chartered, FDIC-insured, full-service, community bank, is dedicated to serving the banking needs of small to mid-size businesses and individuals in Newton, Wellesley, Waltham, and eastern Massachusetts. First Commons Bank combines the industry’s most advanced technology with a highly experienced, onsite, management team to provide clients with superior, personalized service and the highest quality banking experience. It offers a comprehensive portfolio of retail and business banking services, including checking and savings accounts, online banking, ATM/debit cards, money market accounts, certificates of deposit, home equity loans, residential and commercial mortgages, consumer and business loans, and cash management services. First Commons Bank (www.firstcommonsbank.com) is headquartered at 718 Beacon Street in Newton Centre, Massachusetts.

# # #


Industry PR is proudly powered by WordPress.
WordPress